INT137656

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2006
Last Reported 2006
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 4
Disease Relevance 0.70
Pain Relevance 3.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Casp3) peptidase activity (Casp3) mitochondrion (Casp3)
nucleolus (Casp3) nucleus (Casp3) intracellular (Casp3)
Anatomy Link Frequency
NAc 2
Casp3 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 4 99.82 Very High Very High Very High
Nucleus accumbens 18 98.72 Very High Very High Very High
Glutamate 144 97.40 Very High Very High Very High
Hippocampus 12 96.08 Very High Very High Very High
Morphine 15 93.80 High High
opiate 3 85.52 High High
nMDA receptor 6 5.00 Very Low Very Low Very Low
ischemia 3 5.00 Very Low Very Low Very Low
Neurotransmitter 3 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Death 80 97.78 Very High Very High Very High
Osteoporosis 1 86.28 High High
Apoptosis 97 74.40 Quite High
Neurodegenerative Disease 11 5.00 Very Low Very Low Very Low
Toxicity 3 5.00 Very Low Very Low Very Low
Aging 3 5.00 Very Low Very Low Very Low
Disease 3 5.00 Very Low Very Low Very Low
Cv General 4 Under Development 2 5.00 Very Low Very Low Very Low
Injury 2 5.00 Very Low Very Low Very Low
Neuritis 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, systemic administration (5 mg/kg, s.c.) or intrahippocampal infusion (0, 0.1, 1.0, 10, 20 microg per side) of the GR antagonist RU38486 blocked or impaired the formation of CPP in a dose-dependent manner, respectively.
Negative_regulation (impaired) of CPP Binding (formation) of associated with antagonist
1) Confidence 0.21 Published 2006 Journal Hippocampus Section Abstract Doc Link 16897719 Disease Relevance 0 Pain Relevance 0.95
In contrast, systemic administration (5 mg/kg, s.c.) or intrahippocampal infusion (0, 0.1, 1.0, 10, 20 microg per side) of the GR antagonist RU38486 blocked or impaired the formation of CPP in a dose-dependent manner, respectively.
Negative_regulation (blocked) of CPP Binding (formation) of associated with antagonist
2) Confidence 0.21 Published 2006 Journal Hippocampus Section Abstract Doc Link 16897719 Disease Relevance 0 Pain Relevance 0.95
Furthermore, intra-NAc infused RU38486 (10 microg per side) but not DMSO vehicle also prevented the formation of CPP.
Negative_regulation (prevented) of CPP Binding (formation) of in NAc associated with nucleus accumbens
3) Confidence 0.21 Published 2006 Journal Hippocampus Section Abstract Doc Link 16897719 Disease Relevance 0 Pain Relevance 0.95
Our current findings indicate that estrogens prevent glutamate-induced cell death by reducing the upregulation and/or translocation of AIF from the mitochondria into the cytosol as well as by attenuating activity of calpain and caspase-3 in primary cortical cells and HT22 cells, with ?
Negative_regulation (attenuating) of caspase-3 Binding (activity) of associated with glutamate and death
4) Confidence 0.20 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1526740 Disease Relevance 0.70 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox